Novel clinical uses for cord blood derived mesenchymal stromal cells

Olson, Amanda; McNiece, Ian

doi:10.1016/j.jcyt.2015.03.612

Cited by 8 publications

(5 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, umbilical cord blood (UCB) has become an attractive source of stem cells, because of its noninvasive collection procedure and rapid availability from cord blood banking (17,18). Human UCB-derived MSCs (hUCB-MSCs) exhibit higher proliferation capacity and lower immunogenicity compared with BM-MSCs (17,19). Data from a few reports support that UCB-MSCs may have greater immunosuppressive potential than other sources of MSCs (17)(18)(19)(20)(21)(22).…”

Section: Discussionmentioning

confidence: 99%

“…Human UCB-derived MSCs (hUCB-MSCs) exhibit higher proliferation capacity and lower immunogenicity compared with BM-MSCs (17,19). Data from a few reports support that UCB-MSCs may have greater immunosuppressive potential than other sources of MSCs (17)(18)(19)(20)(21)(22). In addition, hUCB-MSCs have shown greater immunosuppressive and regenerative potential than BM-or peripheral blood-derived MSCs in murine wounding model (23).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intravenous allogeneic umbilical cord blood–derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients

Lee¹,

Lee²,

Kim³

et al. 2021

JCI Insight

View full text Add to dashboard Cite

BACKGROUND Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease that causes severe mucocutaneous fragility due to mutations in COL7A1 (encoding type VII collagen [C7]). In this phase I/IIa trial, we evaluated the safety and possible clinical efficacy of intravenous infusion of allogeneic human umbilical cord blood–derived mesenchymal stem cells (hUCB-MSCs) in patients with RDEB. METHODS Four adult and two pediatric patients with RDEB were treated with 3 intravenous injections of hUCB-MSCs (1 × 10 6 to 3 × 10 6 cells/kg) every 2 weeks and followed up for 8–24 months after treatment. The primary endpoint was safety. Secondary endpoints related to efficacy included clinical parameters, such as disease severity score, wound assessment, itch and pain score, and quality of life. C7 expression levels and inflammatory infiltrates in the skin, as well as serum levels of inflammatory markers and neuropeptides, were also assessed. RESULTS Intravenous hUCB-MSC infusions were well tolerated, without serious adverse events. Improvements in the Birmingham Epidermolysis Bullosa Severity Score, body surface area involvement, blister counts, pain, pruritus, and quality of life were observed with maximal effects at 56–112 days after treatment. hUCB-MSC administration induced M2 macrophage polarization and reduced mast cell infiltration in RDEB skin. Serum levels of substance P were decreased after therapy. Increased C7 expression was observed at the dermoepidermal junction in 1 of 6 patients at day 56. CONCLUSION To the best of our knowledge, this is the first clinical trial of systemic administration of allogeneic hUCB-MSCs in patients with RDEB, demonstrating safety and transient clinical benefits. TRIAL REGISTRATION ClinicalTrials.gov NCT04520022. FUNDING This work was supported by Daewoong Pharmaceutical Co. Ltd. and Kangstem Biotech Co. Ltd.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Intravenous allogeneic umbilical cord blood–derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients

Lee¹,

Lee²,

Kim³

et al. 2021

JCI Insight

View full text Add to dashboard Cite

show abstract

“…12 La capacidad de desarrollo condrogénico a partir de CMM ha permitido realizar estudios acerca de su utilidad para el tratamiento de defectos cartilaginosos como ocurre en la osteoartritis, entre estas se combinan estas células con otros compuestos y se crean componente articulares fundamentales para su adecuado funcionamiento y rehabilitación de los pacientes. 13…”

Section: Diferenciación a Tejido Cartilaginosounclassified

“…La terapia con las mismas se basa en dos principios generales: disminución del proceso inflamatorio y la regeneración de los diferentes tejidos haciendo de estos tejidos u órganos completamente funcionales. 13 (Veáse tabla 1) Tabla 1. Campos de uso de CMM 13…”

Section: Otros Usosunclassified

Células madre mesenquimatosas y sus diferentes usos

Martínez-Sánchez

Vergara-Yanez

Herrera-Almanza

2021

cysa

View full text Add to dashboard Cite

Introducción: las células madre mesenquimatosas (CMM) se diferencian de diversos tipos celulares para la regeneración de tejidos, esta característica sumada con la versatilidad del antígeno leucocitario humano (HLA) representan una eficaz alternativa para el tratamiento de enfermedades con tejidos deteriorados. Se pueden obtener a partir de médula ósea, cordón umbilical (CU) y sangre fetal. Objetivo: analizar los tipos de diferenciación de las CMM, sus métodos de extracción y su relación con bancos de sangre de cordón umbilical (BSCU), a fin de demostrar la eficacia de las CMM, en patologías que impliquen alteración de algún tejido u órgano. Metodología: se revisaron varias publicaciones en español e inglés en Pubmed, Clinicalkey y Science Direct; desde 2013 hasta 2020. Se usaron los términos sangre fetal, células madre mesenquimatosas, trasplante de Células Madre de Sangre del Cordón Umbilical y bancos de sangre. Con dicha información se redactó un panorama amplio sobre las células mesenquimales y como estas participan en diversas áreas de la salud, con un énfasis importante en sus usos terapéuticos y lo referente a de donde provienen. Conclusión: a través de la pluripotencialidad de las CMM, se han podido emplear en múltiples patologías pues reestablece tejidos o líneas celulares exitosamente. Así mismo, los recursos para su obtención son claves en la tolerancia de los pacientes, por lo cual una gran opción para su obtención es el CU, que actualmente cuenta con bancos exclusivos para esto.

show abstract

“…MSC are multipotent adult progenitor cells, which can be isolated from various sources, such as bone marrow, placenta, umbilical cord, umbilical cord blood and adipose tissues ( 9 , 10 ). MSCs have the unique abilities of self-renewal, proliferation and multipotent differentiation, and can differentiate into the different cell types of the three germ layers; neurons, adipocytes, osteoblasts, hepatocytes, endothelial cells and islet b cells ( 11 – 13 ). In recent years, MSCs have received attention from researchers worldwide and several features have identified them as promising candidates for the treatment of diseases of the central nervous system.…”

Section: Therapeutic Potential Of Mscs In the Treatment Of Strokementioning

confidence: 99%

Extracellular vesicles in mesenchymal stromal cells: A novel therapeutic strategy for stroke (Review)

Cheng

Guoheng

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

A stroke is a focal cerebral insult that frequently causes severe neurological deficit and mortality. Recent studies have demonstrated that multipotent mesenchymal stromal cells (MSCs) hold great promise for neurovascular remodeling and neurological function recovery following a stroke. Rather than a direct replacement of parenchymal brain cells, the therapeutic mechanism of MSCs is suggested to be the secretion of soluble factors. Specifically, emerging data described MSCs as being able to release extracellular vesicles (EVs), which contain a variety of cargo including proteins, lipids, DNA and various RNA species. The released EVs can target neurocytes and vascular cells and modify the cell's functions by delivering the cargo, which are considered to mediate the neural restoration effects of MSCs. Therefore, EVs may be developed as a novel cell-free therapy for neurological disorders. In the present review, the current advances regarding the components, functions and therapeutic potential of EVs are summarized and the use of MSC-derived EVs as a promising approach in the treatment of stroke are highlighted.

show abstract

Novel clinical uses for cord blood derived mesenchymal stromal cells

Cited by 8 publications

References 61 publications

Intravenous allogeneic umbilical cord blood–derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients

Intravenous allogeneic umbilical cord blood–derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients

Células madre mesenquimatosas y sus diferentes usos

Extracellular vesicles in mesenchymal stromal cells: A novel therapeutic strategy for stroke (Review)

Contact Info

Product

Resources

About